222 related articles for article (PubMed ID: 16778094)
1. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
[TBL] [Abstract][Full Text] [Related]
2. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
5. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
[TBL] [Abstract][Full Text] [Related]
7. Terpenoids and breast cancer chemoprevention.
Rabi T; Bishayee A
Breast Cancer Res Treat; 2009 May; 115(2):223-39. PubMed ID: 18636327
[TBL] [Abstract][Full Text] [Related]
8. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
[TBL] [Abstract][Full Text] [Related]
9. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
10. Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Ranger-Moore J; Alberts DS; Montironi R; Garcia F; Davis J; Frank D; Brewer M; Mariuzzi GM; Bartels HG; Bartels PH
Eur J Cancer; 2005 Sep; 41(13):1875-88. PubMed ID: 16087328
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and surrogacy: relevance to chemoprevention.
Kensler TW; Davidson NE; Groopman JD; Muñoz A
IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
[TBL] [Abstract][Full Text] [Related]
13. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Lippman SM; Heymach JV
Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
Arber N
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371
[TBL] [Abstract][Full Text] [Related]
16. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
17. [Cancer prevention].
Akaza H; Tsuruo T; Saijo N; Sone S; Isonishi S; Ohashi Y; Noguchi S; Kurebayashi J; Kakehi Y; Ishikawa H; Blackledge G
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1499-506. PubMed ID: 16227757
[TBL] [Abstract][Full Text] [Related]
18. Oral cancer prevention and the evolution of molecular-targeted drug development.
Lippman SM; Sudbø J; Hong WK
J Clin Oncol; 2005 Jan; 23(2):346-56. PubMed ID: 15637397
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers and targets for colorectal cancer prevention.
Janakiram NB; Rao CV
Acta Pharmacol Sin; 2008 Jan; 29(1):1-20. PubMed ID: 18158862
[TBL] [Abstract][Full Text] [Related]
20. Development of cancer chemopreventive drugs based on mechanistic approaches.
Steele VE; Kelloff GJ
Mutat Res; 2005 Dec; 591(1-2):16-23. PubMed ID: 16083917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
